Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Application of stable isotope dimethyl labeling for MRM based absolute antigen quantification of influenza vaccine.

Huang SY, Lin MH, Chen YH, Lai CC, Lee MS, Hu AY, Sung WC.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Jan 1;1104:40-48. doi: 10.1016/j.jchromb.2018.09.020. Epub 2018 Sep 21.

PMID:
30428430
2.

External validation of the Cairns Prediction Model (CPM) to predict conversion from laparoscopic to open cholecystectomy.

Hu ASY, Donohue PO, Gunnarsson RK, de Costa A.

Am J Surg. 2018 Nov;216(5):949-954. doi: 10.1016/j.amjsurg.2018.03.016. Epub 2018 Mar 14.

PMID:
29631908
3.

Risk factors for conversion of laparoscopic cholecystectomy to open surgery - A systematic literature review of 30 studies.

Hu ASY, Menon R, Gunnarsson R, de Costa A.

Am J Surg. 2017 Nov;214(5):920-930. doi: 10.1016/j.amjsurg.2017.07.029. Epub 2017 Jul 21. Review.

4.

A fast and efficient purification platform for cell-based influenza viruses by flow-through chromatography.

Tseng YF, Weng TC, Lai CC, Chen PL, Lee MS, Hu AY.

Vaccine. 2018 May 24;36(22):3146-3152. doi: 10.1016/j.vaccine.2017.03.016. Epub 2017 Mar 22.

PMID:
28342667
5.

Functional value of elytra under various stresses in the red flour beetle, Tribolium castaneum.

Linz DM, Hu AW, Sitvarin MI, Tomoyasu Y.

Sci Rep. 2016 Oct 6;6:34813. doi: 10.1038/srep34813.

6.

Evaluation of MDCK cell-derived influenza H7N9 vaccine candidates in ferrets.

Chia MY, Hu AY, Tseng YF, Weng TC, Lai CC, Lin JY, Chen PL, Wang YF, Chao SR, Chang JY, Hwang YS, Yeh CT, Yu CP, Chen YC, Su IJ, Lee MS.

PLoS One. 2015 Mar 23;10(3):e0120793. doi: 10.1371/journal.pone.0120793. eCollection 2015.

7.

Bone Morphogenetic Protein (BMP) signaling in development and human diseases.

Wang RN, Green J, Wang Z, Deng Y, Qiao M, Peabody M, Zhang Q, Ye J, Yan Z, Denduluri S, Idowu O, Li M, Shen C, Hu A, Haydon RC, Kang R, Mok J, Lee MJ, Luu HL, Shi LL.

Genes Dis. 2014 Sep;1(1):87-105.

8.

Formulation and immunological evaluation of a trivalent vaccine comprising emulsified submicron particles and inactivated virions of H5N1/EV71/JEV.

Lin CW, Chang CY, Chen WL, Lin SC, Liao CC, Chang JY, Liu CC, Hu AY, Lu TC, Chou AH, Wu SC, Chong P, Huang MH.

Hum Vaccin Immunother. 2013 Nov;9(11):2378-85. Epub 2013 Jul 9.

9.

Growth, metabolic activity, and productivity of immobilized and freely suspended CHO cells in perfusion culture.

Hilal-Alnaqbi A, Hu AY, Zhang Z, Al-Rubeai M.

Biotechnol Appl Biochem. 2013 Jul-Aug;60(4):436-45. doi: 10.1002/bab.1103. Epub 2013 May 23.

PMID:
23701045
10.

Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development.

Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L.

J Clin Oncol. 2012 Dec 20;30(36):4584-6; author reply 4588-9. doi: 10.1200/JCO.2012.44.1022. Epub 2012 Nov 19. No abstract available.

PMID:
23169510
11.

Less haste, less waste: on recycling and its limits in strand displacement systems.

Condon A, Hu AJ, Ma┼łuch J, Thachuk C.

Interface Focus. 2012 Aug 6;2(4):512-21. doi: 10.1098/rsfs.2011.0106. Epub 2012 Feb 15.

12.

Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates.

Chou AH, Liu CC, Chang CP, Guo MS, Hsieh SY, Yang WH, Chao HJ, Wu CL, Huang JL, Lee MS, Hu AY, Lin SC, Huang YY, Hu MH, Chow YH, Chiang JR, Chang JY, Chong P.

PLoS One. 2012;7(4):e34834. doi: 10.1371/journal.pone.0034834. Epub 2012 Apr 17.

13.

A cell-based backup to speed up pandemic influenza vaccine production.

Lee MS, Hu AY.

Trends Microbiol. 2012 Mar;20(3):103-5. doi: 10.1016/j.tim.2011.12.002. Epub 2012 Jan 16.

PMID:
22257962
14.

Adaptation of high-growth influenza H5N1 vaccine virus in Vero cells: implications for pandemic preparedness.

Tseng YF, Hu AY, Huang ML, Yeh WZ, Weng TC, Chen YS, Chong P, Lee MS.

PLoS One. 2011;6(10):e24057. doi: 10.1371/journal.pone.0024057. Epub 2011 Oct 13.

15.

Production of inactivated influenza H5N1 vaccines from MDCK cells in serum-free medium.

Hu AY, Tseng YF, Weng TC, Liao CC, Wu J, Chou AH, Chao HJ, Gu A, Chen J, Lin SC, Hsiao CH, Wu SC, Chong P.

PLoS One. 2011 Jan 24;6(1):e14578. doi: 10.1371/journal.pone.0014578.

16.

Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice.

Huang MH, Lin SC, Hsiao CH, Chao HJ, Yang HR, Liao CC, Chuang PW, Wu HP, Huang CY, Leng CH, Liu SJ, Chen HW, Chou AH, Hu AY, Chong P.

PLoS One. 2010 Aug 19;5(8):e12279. doi: 10.1371/journal.pone.0012279.

17.

Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines.

Hu AY, Weng TC, Tseng YF, Chen YS, Wu CH, Hsiao S, Chou AH, Chao HJ, Gu A, Wu SC, Chong P, Lee MS.

Vaccine. 2008 Oct 23;26(45):5736-40. doi: 10.1016/j.vaccine.2008.08.015. Epub 2008 Aug 30.

PMID:
18761387

Supplemental Content

Loading ...
Support Center